Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORTHO-NOVUM 7/7/7-28 vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of estrogen (ethinyl estradiol) and progestin (norethindrone) inhibits gonadotropin secretion, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Prevention of pregnancy
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
One tablet orally once daily for 28 consecutive days (21 active tablets followed by 7 placebo tablets). Each active tablet contains 0.035 mg ethinyl estradiol and varying progestin doses: 7 tablets of 0.5 mg norethindrone, 7 tablets of 0.75 mg norethindrone, and 7 tablets of 1 mg norethindrone.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
EE: terminal half-life 13-27 hours (mean ~17 hours); NET: 7-13 hours (mean ~10 hours). Clinical context: steady state reached after 4-7 days; missed pills may reduce contraceptive efficacy.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Ethinyl estradiol and norethindrone undergo hepatic metabolism via CYP3A4 and other CYP450 enzymes. Conjugation and sulfation also occur.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Ethinyl estradiol (EE) is excreted in urine (40%) and feces (60%) as glucuronide and sulfate conjugates. Norethindrone (NET) is excreted primarily in urine (60-80%) as glucuronide conjugates, with 10% in feces. Biliary excretion contributes minimally.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
EE: 98% bound to albumin; induces SHBG synthesis, increasing binding capacity. NET: 61% bound to albumin, 36% bound to SHBG.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
EE: 2.5-5.0 L/kg (mean 4 L/kg); large Vd due to extensive tissue distribution. NET: 1.5-4.0 L/kg (mean 2.5 L/kg); distributes into breast milk.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
EE: 38-48% due to first-pass metabolism (sulfation in gut wall and 2-hydroxylation in liver). NET: 50-77% (mean 64%) with high first-pass metabolism.
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No specific dosage adjustments recommended for renal impairment. Use with caution in severe renal impairment due to potential for fluid retention and hypertension.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Contraindicated in acute hepatitis, severe cirrhosis, or liver tumors. For mild hepatic impairment (Child-Pugh A), use with caution; no specific dose adjustment established. Not recommended in moderate to severe impairment (Child-Pugh B or C) due to reduced metabolism of steroid hormones.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Not indicated for premenarchal girls. For postmenarchal adolescents, dosage is the same as adults (one tablet daily) but initiation should be based on clinical judgment and individual risk factors.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Not indicated for postmenopausal women. No specific dosing recommendations; use not appropriate in this age group due to lack of contraceptive need and potential increased risk of vascular events.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (>15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders; use caution in patients with cardiovascular risk factors. Monitor blood pressure. Discontinue if jaundice, visual disturbances, or migraine occurs. May affect glucose tolerance. Use with caution in patients with history of depression.
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Thrombophlebitis or thromboembolic disorders; history of deep vein thrombosis or pulmonary embolism; cerebrovascular or coronary artery disease; known or suspected breast cancer; endometrial cancer or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component; cigarette smoking in women over age 35.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No specific food restrictions; grapefruit juice may increase ethinyl estradiol levels and should be avoided or minimized. High-fat meals may slightly increase absorption but not clinically significant.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
Combined hormonal contraceptives (CHCs) including ORTHO-NOVUM 7/7/7-28 are contraindicated during pregnancy. First trimester exposure: no consistent evidence of major malformations (e.g., VACTERL) from epidemiologic studies, but a small increased risk of cardiovascular defects and limb reduction defects cannot be excluded. Second and third trimester exposure: risk of maternal and fetal adverse outcomes, including fetal growth restriction, preterm delivery, and potential masculinization of female fetuses from progestins. Use is contraindicated once pregnancy is suspected or confirmed.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
CHCs like ORTHO-NOVUM 7/7/7-28 may reduce milk production and quality, especially in early postpartum. Small amounts of ethinyl estradiol and norethindrone are excreted into breast milk; estimated infant dose is <1% of maternal weight-adjusted dose. Milk-to-plasma (M/P) ratio for norethindrone is approximately 0.1–0.5; ethinyl estradiol M/P ratio is not well defined. Use during lactation is generally not recommended; progestin-only contraceptives are preferred. If used, initiate after established breastfeeding (≥6 months).
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
ORTHO-NOVUM 7/7/7-28 is contraindicated during pregnancy. No dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are not relevant due to contraindication.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
Fixed-dose combination of norethindrone and ethinyl estradiol; pill sequence has 7 white (0.5mg norethindrone/35mcg EE), 7 light peach (0.75mg/35mcg), 7 peach (1mg/35mcg), 7 green (placebo). Missed pills increase breakthrough bleeding risk; if one pill missed, take as soon as remembered; if two or more, use backup contraception for 7 days. Consider progestin-only alternatives in patients with migraine with aura, uncontrolled hypertension, or smoking >35. Potential for reduced efficacy with enzyme-inducing antiepileptics (e.g., carbamazepine) and rifampin. Increased VTE risk, especially in first year of use. Estrogen-containing contraceptives can increase hepatic clearance of some drugs. Not suitable for breastfeeding within first 6 weeks postpartum due to estrogen effect on milk supply.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one pill daily at the same time; start on first day of menstrual period or first Sunday after period begins (check package instructions).,The pill pack has 3 different colored active pills (white, light peach, peach) with increasing progestin dose, followed by 7 green placebo pills; continue taking daily even during placebo week.,If you miss one active pill, take it as soon as remembered and take next pill at usual time (may take 2 pills in one day).,If two or more active pills are missed, take the last missed pill now, discard others, continue with remaining pills; use backup contraception (e.g., condoms) for next 7 days.,Common side effects: nausea, breast tenderness, spotting (especially in first few months); report leg swelling, chest pain, severe headache, or vision changes.,Avoid grapefruit juice as it may increase estrogen levels; no known food restrictions otherwise.,Smoking increases risk of serious cardiovascular events; advise smoking cessation.,Do not use while pregnant; if pregnancy suspected, discontinue and consult healthcare provider.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORTHO-NOVUM 7/7/7-28 vs ALTAVERA, answered by our medical review team.
ORTHO-NOVUM 7/7/7-28 is a Oral Contraceptive that works by Combination of estrogen (ethinyl estradiol) and progestin (norethindrone) inhibits gonadotropin secretion, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORTHO-NOVUM 7/7/7-28 and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORTHO-NOVUM 7/7/7-28 is: One tablet orally once daily for 28 consecutive days (21 active tablets followed by 7 placebo tablets). Each active tablet contains 0.035 mg ethinyl estradiol and varying progestin doses: 7 tablets of 0.5 mg norethindrone, 7 tablets of 0.75 mg norethindrone, and 7 tablets of 1 mg norethindrone.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORTHO-NOVUM 7/7/7-28 and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORTHO-NOVUM 7/7/7-28 is classified as Category C. Combined hormonal contraceptives (CHCs) including ORTHO-NOVUM 7/7/7-28 are contraindicated during pregnancy. First trimester exposure: no consistent evidence of major malformations. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.